Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern
Recommend:
0

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago AMERICAN : Trademark Application for "PIECING TOGETHER A BRIGHTER FUTURE" Filed
<1m ago AMERICAN : An Application for the Trademark "BANKERS PROFESSIONAL EDGE" Has Been Filed by American International Group
<1m ago An Application for the Trademark "HOME STATE HEALTH" Has Been Filed by Centene
<1m ago AMERICAN : Trademark Application for "VCP MANAGED ASSET ALLOCATION SAST PORTFOLIO" Filed
<1m ago AMERICAN : Trademark Application for "LEX PHYSICIANS ELITE" Filed
<1m ago AMERICAN : An Application for the Trademark "AIG ROPTERM MVP" Has Been Filed by American International Group
<1m ago AMERICAN : Trademark Application for "SUNAMERICA DYNAMIC STRATEGY PORTFOLIO" Filed
<1m ago AMERICAN : An Application for the Trademark "CPL SPECIALTY TRADE PROTECT" Has Been Filed by American International Group
<1m ago AMERICAN : Trademark Application for "W WIN WARRANTY INFORMATION NETWORK" Filed
<1m ago AMERICAN : Trademark Application for "POLARIS INCOME PLUS" Filed
Latest news
Advertisement
Hot News 
RENEWABLE ENERGY : Findings from National University of Defense Technology Update Knowledge of General Mathematics (An Improved Dispatch Strategy of a Grid-Connected...
AFREN : Oil Explorer Afren Suspends Top Executives
GFI : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of GFI Group Inc. Stockholders
REDHALL : Trading Update
HYDER CONSULTING : Agrees To Be Acquired by Arcadis At 39% Premium
Most Read News
1d ago JPMORGAN CHASE : Announces $30 Million for Small Business Network Growth
1d ago BANCO MACRO : Argentina fails to reach debt agreement, default imminent
1d ago AMC NETWORKS : wants stake in BBC America - source
1d ago MOLECULAR MEDICINE : Researchers from Huazhong University of Science and Technology Provide Details of New Studies and Findings in the Area of Molecular Medicine (Growth...
1d ago BANCO ESPIRITO SANTO : BES seeks capital as key staff suspended over massive losses
Most recommended articles
3m ago Euro zone inflation drops to near five-year low in July
4m ago London platinum, palladium fixing co seeks third-party administrator
8m ago BG : profits rise but Egypt woes weigh
8m agoDJBANCO SANTANDER : Santander Reports Rise in Second-Quarter Profit
9m agoDJROYAL DUTCH SHELL A : Second-Quarter Profit Jumps
Dynamic quotes  
ON
| OFF